Parexel Launches Genomic Medicine Team
The team joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments and expands capabilities in genomic-based drug development.
Parexel has expanded services and capabilities in genomic-based drug development with its Genomic Medicine team. The team is comprised of more than 15 scientists with combined expertise in genomics, drug discovery, and drug development, who joined Parexel from GlaxoSmithKline’s Genetics and Computational Biology departments. The team will meet clients’ expected increased needs for the number of personalized medicines that will require genomic information to inform decision-making on the clinical utility and value for the intended patient population.
Read the full release.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
